The New American Addiction: How Weight-Loss Drugs Could Create the Next Epidemic
Article Sidebar
Main Article Content
Abstract
GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) have rapidly gained popularity for obesity treatment, with unprecedented public enthusiasm and off-label use in otherwise healthy populations. While these agents demonstrate substantial weight-loss efficacy, emerging concerns highlight potential pharmaceutical dependency, ethical dilemmas, and long-term safety uncertainties. This article critically examines the mechanisms, benefits, and risks of GLP-1 agonists, emphasizing the need for regulatory oversight, psychological safeguards, and integration with lifestyle interventions. We argue for a balanced approach in which pharmacotherapy serves as a temporary adjunct, rather than a substitute, for evidence-based exercise, nutrition, and behavioral strategies essential to sustainable metabolic health.
Article Details
Copyright (c) 2025 Fredrick Peters
This work is licensed under a Creative Commons Attribution 4.0 International License.
Brown T. Public perceptions and ethical considerations of GLP-1 agonists in obesity care. Obes Rev. 2023;24(3):e13550.
Patel R, Jones M. The rise of GLP-1 receptor agonists: Trends and implications. J Obes Res. 2022;30(6):455–63.
Hruby A, Hu FB. The epidemiology of obesity: A big picture. Pharmacoeconomics. 2022;40(2):101–15.
Rubino D. Long-term effects of GLP-1 receptor agonists in obesity treatment: What we do and don’t know. Obes Rev. 2023;24(2):e13528.
Wilding JPH. Weight regain after withdrawal of semaglutide: A randomized clinical trial. Lancet Diabetes Endocrinol. 2022;10(11):840–9.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–16. Available from: https://doi.org/10.1056/NEJMoa2206038
Garvey WT. Safety of GLP-1 receptor agonists: Current evidence and future directions. Diabetes Obes Metab. 2023;25(1):10–22.
Wharton S. Clinical practice guidelines for the treatment of obesity in adults. CMAJ. 2021;193(31):E1120–E1136.
Greenfield J. Ethical challenges in prescribing GLP-1 receptor agonists for obesity. Lancet Diabetes Endocrinol. 2022;10(12):890–9.
U.S. Food and Drug Administration. Consumer warning: The dangers of unregulated compounded semaglutide. FDA Public Health Advisory. 2024.
Jakicic JM. Role of physical activity and exercise in obesity treatment. J Clin Endocrinol Metab. 2022;107(4):1036–50.
Swift DL. The effects of exercise and physical activity on weight loss and maintenance. Prog Cardiovasc Dis. 2021;67(3):143–52.
Folli F. Sarcopenia, frailty, and rapid weight loss: Clinical implications. J Cachexia Sarcopenia Muscle. 2022;13(4):1800–12.